InVivo Therapeutics Holdings Corp. (NVIV), a biomaterials company with innovative technologies for drug delivery with a focus on treatment of spinal cord injuries, today reported financial results for the quarter ended March 31, 2014.
Mark Perrin, Chief Executive Officer of InVivo, said, “As we previously reported, we are excited to have our first clinical site in the final stages of surgical training for our scaffold pilot study and expect to have patient enrollment open by the end of May.
Help employers find you! Check out all the jobs and post your resume.
